Facultad de Medicina Humana, Universidad Peruana de Ciencias Aplicadas, Lima, Peru.
Knowledge and Evaluation Research Unit, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Endocrine. 2023 Mar;79(3):430-436. doi: 10.1007/s12020-022-03263-w. Epub 2022 Dec 2.
Statin intolerance is a key barrier to the effective prevention of atherosclerotic cardiovascular disease (ASCVD). Experts do not agree on what it is and how to respond to this problem clinically.
To characterize the range of expert recommendations about the care of patients with statin intolerance.
Systematic review registered in PROSPERO that searched on April 1 2022 in PubMed, EMBASE, Scopus, Cochrane, online textbooks, and specialty textbooks for expert reviews (e.g., review articles and book chapters), systematic reviews, or clinical practice guidelines published in the past 5 years without language restriction. Authors working in duplicate extracted definitions, management recommendations, and supportive evidence cited.
We identified 26 eligible articles, none of which described a systematic method to summarize the evidence or to develop and grade recommendations. Of these, 14 (54%) offered a definition of statin intolerance. A sequenced approach to management of statin intolerance was suggested in 24 (92%) articles describing 12 different approaches without supporting evidence of efficacy. Investigating for other causes was the most common first step. All authors suggested rechallenging after a washout period with either the same or other statin. Few considered nonlipid approaches to reducing ASCVD risk and none recommended involving patients in shared decision making.
We found substantial variability in the definition and management of statin intolerance among experts. Few focused on ASCVD risk reduction and none promoted the participation of patients in shared decision making about how to address the threat of ASCVD with or without statins.
他汀类药物不耐受是有效预防动脉粥样硬化性心血管疾病(ASCVD)的主要障碍。专家们对于他汀类药物不耐受的定义以及如何在临床上应对这一问题存在分歧。
描述专家对他汀类药物不耐受患者护理的建议范围。
系统检索 PROSPERO 注册的文献,于 2022 年 4 月 1 日在 PubMed、EMBASE、Scopus、Cochrane、在线教科书和专业教科书上检索了关于专家评论(例如,综述文章和章节)、系统评价或过去 5 年中发布的临床实践指南,无语言限制。作者们重复工作,提取定义、管理建议和引用的支持证据。
我们确定了 26 篇符合条件的文章,其中没有一篇描述了总结证据或制定和分级建议的系统方法。其中,14 篇(54%)对他汀类药物不耐受给出了定义。24 篇(92%)描述了他汀类药物不耐受管理的序贯方法,提出了 12 种不同的方法,但没有支持有效性的证据。首先调查其他原因是最常见的步骤。所有作者都建议在洗脱期后用相同或其他他汀类药物重新进行挑战。很少有人考虑采用非降脂方法来降低 ASCVD 风险,也没有人建议让患者参与关于是否使用他汀类药物或不使用他汀类药物来处理 ASCVD 威胁的共同决策。
我们发现专家在他汀类药物不耐受的定义和管理方面存在很大差异。很少有人关注 ASCVD 风险降低,也没有人提倡让患者参与关于是否使用他汀类药物或不使用他汀类药物来处理 ASCVD 威胁的共同决策。